Association Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials

被引:1
|
作者
Schpero, William L. [1 ,2 ]
Takvorian, Samuel U. [3 ,4 ,5 ]
Blickstein, Daniel [6 ]
Shafquat, Afrah [6 ]
Liu, Jingshu [6 ]
Chatterjee, Arnaub K. [7 ]
Lamont, Elizabeth B. [6 ]
Chatterjee, Paula [4 ,5 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Populat Hlth Sci, Div Hlth Policy & Econ, New York, NY 14850 USA
[2] Cornell Univ, Ctr Hlth Equ, New York, NY 14850 USA
[3] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[5] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA
[6] Dassault Syst Co, Medidata AI, New York, NY USA
[7] TriNetX, Cambridge, MA USA
关键词
INSURANCE-COVERAGE; INCOME LEVEL; PARTICIPATION; BARRIERS; ENROLLMENT; IMPACT;
D O I
10.1200/JCO.23.01149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEIt is unknown whether Medicaid expansion under the Affordable Care Act (ACA) or state-level policies mandating Medicaid coverage of the routine costs of clinical trial participation have ameliorated longstanding racial and ethnic disparities in cancer clinical trial enrollment.METHODSWe conducted a retrospective, cross-sectional difference-in-differences analysis examining the effect of Medicaid expansion on rates of enrollment for Black or Hispanic nonelderly adults in nonobservational, US cancer clinical trials using data from Medidata's Rave platform for 2012-2019. We examined heterogeneity in this effect on the basis of whether states had pre-existing mandates requiring Medicaid coverage of the routine costs of clinical trial participation.RESULTSThe study included 47,870 participants across 1,353 clinical trials and 344 clinical trial sites. In expansion states, the proportion of participants who were Black or Hispanic increased from 16.7% before expansion to 17.2% after Medicaid expansion (0.5 percentage point [PP] change [95% CI, -1.1 to 2.0]). In nonexpansion states, this proportion increased from 19.8% before 2014 (when the first states expanded eligibility under the ACA) to 20.4% after 2014 (0.6 PP change [95% CI, -2.3 to 3.5]). These trends yielded a nonsignificant difference-in-differences estimate of 0.9 PP (95% CI, -2.6 to 4.4). Medicaid expansion was associated with a 5.3 PP (95% CI, 1.9 to 8.7) increase in the enrollment of Black or Hispanic participants in states with mandates requiring Medicaid coverage of the routine costs of trial participation, but not in states without mandates (-0.3 PP [95% CI, -4.5 to 3.9]).CONCLUSIONMedicaid expansion was not associated with a significant increase in the proportion of Black or Hispanic oncology trial participants overall, but was associated with an increase specifically in states that mandated Medicaid coverage of the routine costs of trial participation.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)
    Freedman, Rachel A.
    Dockter, Travis J.
    Lafky, Jacqueline M.
    Hurria, Arti
    Muss, Hyman J.
    Cohen, Harvey J.
    Jatoi, Aminah
    Kemeny, M. Margaret
    Ruddy, Kathryn J.
    ONCOLOGIST, 2018, 23 (09): : 1016 - 1023
  • [22] SILENT CRISIS: A CALL FOR CLINICAL TRIALS ENROLLMENT WITH HISPANIC CANCER PATIENTS
    Petty, Marjorie
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [23] The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer
    Kaas, R
    Hart, AAM
    Rutgers, EJT
    BREAST, 2005, 14 (04): : 310 - 316
  • [24] Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials
    Unger, Joseph M.
    Xiao, Hong
    Vaidya, Riha
    LeBlanc, Michael
    Hershman, Dawn L.
    JAMA ONCOLOGY, 2023, 9 (10) : 1371 - 1379
  • [25] Negative results in cancer clinical trials - equivalence or poor accrual?
    Costa, LJM
    Xavier, ACG
    del Giglio, A
    CONTROLLED CLINICAL TRIALS, 2004, 25 (05): : 525 - 533
  • [26] Association of Industry Sponsorship With Cancer Clinical Trial Accrual
    Pasalic, Dario
    Tang, Chad
    Jagsi, Reshma
    Fuller, C. David
    Koong, Albert C.
    Ludmir, Ethan B.
    JAMA ONCOLOGY, 2020, 6 (10) : 1625 - 1627
  • [27] Accrual to lung cancer clinical trials - a single centre experience
    Plant, R.
    Walter, H.
    Samuel, D.
    Fennell, D. A.
    Ahmed, S. I.
    LUNG CANCER, 2014, 83 : S15 - S16
  • [28] Enhancing accrual to clinical trials of adolescents and young adults with cancer
    Fern, Lorna A.
    Taylor, Rachel M.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (09)
  • [29] Strategies for increasing accrual in cancer clinical trials: What is the evidence?
    Michaels, Margo
    Weiss, Elisa S.
    Sae-Hau, Maria
    Illei, Dora
    Lilly, Bethany
    Szumita, Leah
    Connell, Brian
    Lee, Marialanna
    Cooks, Eric
    McPheeters, Melissa
    CANCER MEDICINE, 2024, 13 (10):
  • [30] Smoking cessation interventions for Black and Hispanic cancer patients: A systematic review of tobacco trials
    Strauss, Nicole
    Rabin, Julia
    Temel, Brandon
    Philpotts, Lisa
    Ostroff, Jamie
    Park, Elyse R.
    Perez, Giselle K.
    PSYCHO-ONCOLOGY, 2017, 26 : 87 - 87